Featuring an interview with Prof Alberico Catapano.

Dyslipidaemia commonly co-occurs with type 2 diabetes, and is a major risk factor for cardiovascular disease. To prevent this condition, all recent guidelines recommend reducing LDL cholesterol concentrations in the blood to near-normal levels, particularly in those with elevated cardiovascular risk. This episode provides a quick overview of dyslipdaemia in diabetes before Prof Alberico Catapano provides his top tips for helping patients bring lipids under control.

This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education.

A series of expert interviews conducted at EASD 2019. This includes:

This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education.

Featuring an expert interview with Professor Steve Bain. This episode summarises the major diabetes-related announcement at the 2019 ESC Congress in Paris. This includes the DAPA-HF trial, the new ESC guidelines (developed in collaboration with the EASD) and special population studies.

This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education.

With the ESC 2019 Congress and EASD Annual Meeting taking place over this month, we are slightly changing the release schedule. Our team will be attending both meetings to produce special episodes summarising key highlights, which will be released ~1 week after each conference.

Stay tuned for more information

This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education.

Featuring an interview with Dr William Alazawi.

Non-alcoholic fatty liver disease (NAFLD) is of increasing concern among people with type 2 diabetes. This condition, where an abnormal amount of fat is stored in liver cells, is associated with non-alcohol steathepatitis (NASH), which in turn can progress to fibrosis, cirrhosis and liver cancer. This episode provides a quick overview of NASH in diabetes before Dr William Alazawi, clinical lead for NASH for the Bart's Health NHS trust, provides his recommendations for patients with abnormal liver function.

This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education.

Featuring an interview with Professor Ronald Goldenberg.

An overview of the co-occurrence of obesity and diabetes. This includes the effects of bariatric surgery, the underlying genetic factors of obesity, and recommended treatment approaches. Professor Goldenberg discusses practical advice for working together with patients to achieve normalisation of body weight and blood glucose

This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education.

Featuring an interview with Professor Carel le Roux

An overview of  recent data regarding the renal effects of SGLT2 inhibitors, GLP-1 RAs and DPP-4s. After a 5 minute data summary, Professor Le Roux provides his insight in helping patients achieve multifactorial treatment targets.

This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education.

An overview of new and recent data presented during ADA 2019. This includes:

Featuring an interview with Professor Steve Bain.

This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education.

A highlight of PIONEER trial results, released during ADA 2019. This includes:

Featuring an interview with Professor Steve Bain

This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education.

An introduction to the podcast - who we are, and why we're doing this